tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Collegium Pharmaceutical Inc

COLL
Add to Watchlist
35.390USD
-0.590-1.64%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.15BMarket Cap
15.00P/E TTM

Collegium Pharmaceutical Inc

35.390
-0.590-1.64%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

COLL Financials

See Collegium Pharmaceutical Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Collegium Pharmaceutical Inc Earnings Date

Latest Release
Aug 6, 2026
EPS / Forecast
--/1.72
Revenue / Forecast
--/201.21M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
780.57M
23.62%
EPS(YoY)
1.98
-7.51%
Analyst Rating
BUY
2026/08/02
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
494.28%0.45
37.13%0.54
244.87%1.00
-37.69%0.38
-91.13%0.08
-60.50%0.39
-52.68%0.29
60.91%0.60
268.84%0.86
561.45%0.99
--0.61
--0.38
---0.51
---0.21
----
----
----
----
----
----
Revenue
8.87%193.52M
12.92%205.45M
31.42%209.36M
29.41%188.00M
22.66%177.76M
21.51%181.95M
16.53%159.30M
7.18%145.28M
0.11%144.92M
15.53%149.75M
7.63%136.71M
9.71%135.55M
72.85%144.77M
373.72%129.62M
61.10%127.01M
48.96%123.55M
-4.53%83.75M
-64.13%27.36M
-0.42%78.84M
6.26%82.94M
Net Profit
499.75%14.50M
35.31%16.96M
237.51%31.51M
-38.88%11.98M
-91.28%2.42M
-60.75%12.54M
-54.76%9.34M
50.73%19.61M
259.03%27.71M
543.67%31.94M
4415.10%20.63M
350.57%13.01M
-33.34%-17.43M
71.24%-7.20M
-94.32%457.00K
-107.13%-5.19M
-183.44%-13.07M
-459.79%-25.03M
-28.71%8.05M
803.98%72.84M
Net Margin
450.90%7.49%
19.84%8.26%
156.81%15.05%
-52.77%6.37%
-92.89%1.36%
-67.70%6.89%
-61.18%5.86%
40.64%13.50%
258.86%19.12%
484.04%21.33%
--15.09%
--9.60%
---12.04%
---5.55%
----
----
----
----
----
----
Gross Margin
10.66%60.59%
15.67%62.49%
1.54%61.70%
-7.77%57.65%
-13.24%54.75%
-14.52%54.02%
3.43%60.76%
14.76%62.51%
18.03%63.11%
50.09%63.19%
--58.75%
--54.47%
--53.47%
--42.10%
----
----
----
----
----
----
Debt to assets ratio
8.98%55.96%
-4.68%48.85%
-5.20%50.28%
-1.54%51.67%
-8.18%51.35%
-12.19%51.24%
-12.17%53.04%
-15.59%52.48%
-14.94%55.92%
-2.25%58.35%
--60.38%
--62.18%
--65.74%
--59.70%
----
----
----
----
----
----
Income Statement
Revenue
8.87%193.52M
12.92%205.45M
31.42%209.36M
29.41%188.00M
22.66%177.76M
21.51%181.95M
16.53%159.30M
7.18%145.28M
0.11%144.92M
15.53%149.75M
7.63%136.71M
9.71%135.55M
72.85%144.77M
373.72%129.62M
61.10%127.01M
48.96%123.55M
-4.53%83.75M
-64.13%27.36M
-0.42%78.84M
6.26%82.94M
Operating profit
67.06%37.07M
54.23%61.14M
21.84%66.68M
-24.83%35.68M
-55.15%22.19M
-35.74%39.64M
21.58%54.73M
33.22%47.47M
49.35%49.47M
270.92%61.69M
115.06%45.01M
142.58%35.63M
93.14%33.13M
156.29%16.63M
47.93%20.93M
-10.48%14.69M
-19.06%17.15M
-297.01%-29.54M
-27.91%14.15M
-0.85%16.41M
Net Profit
499.75%14.50M
35.31%16.96M
237.51%31.51M
-38.88%11.98M
-91.28%2.42M
-60.75%12.54M
-54.76%9.34M
50.73%19.61M
259.03%27.71M
543.67%31.94M
4415.10%20.63M
350.57%13.01M
-33.34%-17.43M
71.24%-7.20M
-94.32%457.00K
-107.13%-5.19M
-183.44%-13.07M
-459.79%-25.03M
-28.71%8.05M
803.98%72.84M
Balance Sheet
Current assets
41.34%745.67M
43.37%691.41M
38.32%613.87M
7.65%549.21M
-2.17%527.55M
-10.29%482.26M
-17.37%443.81M
-5.04%510.20M
8.22%539.26M
28.00%537.60M
32.54%537.09M
31.12%537.30M
37.03%498.30M
33.10%419.99M
11.56%405.22M
28.64%409.77M
22.72%363.64M
13.55%315.54M
38.57%363.24M
27.00%318.53M
Total current liabilities
-10.63%434.97M
-13.64%440.03M
-1.41%452.93M
0.63%464.61M
9.02%486.71M
11.27%509.51M
-1.12%459.43M
6.13%461.72M
8.17%446.44M
5.58%457.92M
12.09%464.61M
4.81%435.06M
10.47%412.70M
55.14%433.73M
54.10%414.50M
82.99%415.09M
62.30%373.57M
16.75%279.57M
10.95%268.97M
-10.02%226.84M
Total assets
1.26%1.65B
-0.41%1.66B
-1.70%1.61B
51.19%1.59B
46.41%1.63B
45.51%1.66B
38.86%1.64B
-13.22%1.05B
-8.24%1.11B
-2.63%1.14B
-1.95%1.18B
-2.54%1.21B
-2.56%1.21B
69.65%1.17B
61.89%1.20B
74.51%1.25B
92.88%1.25B
7.49%692.08M
15.21%741.80M
10.34%713.74M
Total liabilities
-4.11%1.34B
-5.55%1.36B
-4.88%1.33B
62.57%1.36B
56.59%1.40B
51.36%1.43B
40.27%1.40B
-17.40%836.80M
-13.77%892.08M
-3.21%947.88M
-0.50%998.71M
-3.33%1.01B
-1.48%1.03B
100.20%979.29M
104.55%1.00B
127.49%1.05B
120.59%1.05B
6.85%489.15M
4.15%490.71M
-6.20%460.67M
Total equity
33.27%312.42M
31.83%301.68M
17.30%274.81M
7.21%232.21M
5.52%234.43M
17.10%228.84M
30.98%234.28M
7.86%216.58M
23.61%222.17M
0.30%195.43M
-9.29%178.87M
1.62%200.81M
-8.34%179.73M
-3.98%194.84M
-21.47%197.19M
-21.91%197.61M
15.32%196.08M
9.08%202.93M
45.40%251.09M
62.46%253.07M
Cash Flow Statement
Net operating income
3.10%57.11M
45.37%123.05M
971.63%78.44M
7.48%72.44M
-10.56%55.40M
15.42%84.64M
-112.16%-9.00M
-32.41%67.40M
123.83%61.94M
10.57%73.34M
73.06%74.02M
146.53%99.72M
209.31%27.67M
83.23%66.33M
147.88%42.77M
36.96%40.45M
-223.07%-25.32M
60.33%36.20M
-49.52%17.25M
-32.65%29.54M
Net investment
116.81%1.63M
-70.63%-20.07M
87.60%-30.87M
67.27%-2.92M
46.60%-9.68M
53.13%-11.76M
-6413.95%-248.96M
78.65%-8.91M
-10200.00%-18.13M
-2569.89%-25.10M
-3282.30%-3.82M
-8949.24%-41.72M
99.97%-176.00K
-82.52%-940.00K
59.06%-113.00K
36.41%-461.00K
-133586.21%-572.18M
65.23%-515.00K
88.51%-276.00K
67.65%-725.00K
Net financing
15.43%-21.34M
47.14%-21.82M
-109.94%-14.82M
57.65%-48.37M
53.39%-25.24M
39.14%-41.28M
256.19%149.03M
-152.47%-114.21M
-179.28%-54.15M
-162.66%-67.83M
-205.30%-95.41M
-88.75%-45.24M
-86.81%68.30M
39.24%-25.82M
-17.90%-31.25M
-171.45%-23.97M
4614.86%517.76M
-242.64%-42.50M
-120.31%-26.51M
27.70%-8.83M

FAQs

What is the total revenue of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its total revenue reached 780.57M, with a year-on-year change of 631.45M.

What are the current assets of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its current assets were 691.41M, with a year-on-year change of 43.37.

What are the total assets of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its total assets of Collegium Pharmaceutical Inc were 1.66B, with a year-on-year change of -0.41.

What are the total liabilities of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its total liabilities of Collegium Pharmaceutical Inc were 1.36B, with a year-on-year change of -5.55.

What is the total equity of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its total equity of Collegium Pharmaceutical Inc was 301.68M, with a year-on-year change of 31.83.

What is the net operating income of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its net operating income of Collegium Pharmaceutical Inc was 187.08M, with a year-on-year change of -2.21.

What is the net investment of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its net investment of Collegium Pharmaceutical Inc was -63.53M, with a year-on-year change of 77.92.

What is the net financing of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its net financing of Collegium Pharmaceutical Inc was -110.25M, with a year-on-year change of -81.91.

What is the Earnings Per Share (EPS) of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its Earnings Per Share (EPS) was 1.98, with a year-on-year change of -7.51.

What is the net income of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its net income was 62.87M, with a year-on-year change of -9.13.

What is the net margin of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its net profit margin was 8.05, with a year-on-year change of -26.49.

What is the gross margin of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its gross margin was 59.35, with a year-on-year change of -0.69.

What is the debt-to-asset ratio of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its debt-to-asset ratio was 56.18, with a year-on-year change of 9.64.

What is the Return on Equity (ROE) of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its Return on Equity (ROE) was 23.70, with a year-on-year change of -27.33.

What is the Return on Assets (ROA) of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its Return on Assets (ROA) was 3.79, with a year-on-year change of -23.19.

What is the operating profit of Collegium Pharmaceutical Inc?

According to Collegium Pharmaceutical Inc's FY2025 earnings report, its operating profit was 187.08M, with a year-on-year change of -2.21.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy